TARO — Taro Pharmaceutical Industries Share Price
0.000.00%
Last trade - 00:00- $1.58bn
- $677.95m
- $572.95m
- 98
- 55
- 90
- 95
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.89 | ||
| Price to Tang. Book | 0.9 | ||
| Price to Free Cashflow | 18.37 | ||
| Price to Sales | 2.59 | ||
| EV to EBITDA | 12.18 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.23% | ||
| Return on Equity | 2.61% | ||
| Operating Margin | 3.6% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 669.89 | 644.77 | 548.97 | 561.35 | 572.95 | 618.07 | n/a | -2.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +34.91 | -11.21 | n/a | n/a | -75.56 | +62.48 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Directors
- Dilip Shanghvi CHM (65)
- Uday Baldota CEO (51)
- Abhay Gandhi VCH (56)
- Erik Zwicker VPR (41)
- Michele Visosky VPR (55)
- Victoria Chester VPR (56)
- Itamar Karsenti VPR (49)
- Avi Avramoff VRD (56)
- Vikash Agarwal VBD (46)
- Jayesh Shah OTH (65)
- James Kedrowski DRC (69)
- Sudhir Valia DRC (64)
- Linda Benshoshan IND (56)
- Dov Pekelman IND (81)
- Robert Stein IND (70)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 3rd, 1959
- Public Since
- January 1st, 1961
- No. of Employees
- 1,554
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 37,587,231
- Address
- 14 Hakitor Street,, HAIFA, 2624761
- Web
- https://www.taro.com/
- Phone
- +972 48475700
- Auditors
- BDO Ziv Haft
Upcoming Events for TARO
Q1 2025 Taro Pharmaceutical Industries Ltd Earnings Release
Similar to TARO
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
What is the Taro Pharmaceutical Industries share price?
As of Today at 19:21 UTC, shares in Taro Pharmaceutical Industries are trading at $42.04. This share price information is delayed by 15 minutes.
How has the Taro Pharmaceutical Industries share price performed this year?
Shares in Taro Pharmaceutical Industries last closed at $42.04 and the price had moved by +68.97% over the past 365 days. In terms of relative price strength the Taro Pharmaceutical Industries share price has outperformed the S&P500 Index by +36.46% over the past year.
What are the analyst and broker recommendations for Taro Pharmaceutical Industries?
The overall consensus recommendation for Taro Pharmaceutical Industries is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Taro Pharmaceutical Industries dividend yield?
Taro Pharmaceutical Industries does not currently pay a dividend.
Does Taro Pharmaceutical Industries pay a dividend?
Taro Pharmaceutical Industries does not currently pay a dividend.
When does Taro Pharmaceutical Industries next pay dividends?
Taro Pharmaceutical Industries does not currently pay a dividend.
How do I buy Taro Pharmaceutical Industries shares?
To buy shares in Taro Pharmaceutical Industries you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Taro Pharmaceutical Industries?
As of the previous close price of $42.04, shares in Taro Pharmaceutical Industries had a market capitalisation of $1.58bn.
Where are Taro Pharmaceutical Industries shares listed?
Here are the trading details for Taro Pharmaceutical Industries:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: TARO
What kind of share is Taro Pharmaceutical Industries?
Based on an overall assessment of its quality, value and momentum Taro Pharmaceutical Industries is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Taro Pharmaceutical Industries share price forecast for 2024?
The analyst consensus target price for shares in Taro Pharmaceutical Industries is $43.00. That is 2.28% above the last closing price of $42.04.
Analysts covering Taro Pharmaceutical Industries currently have a consensus Earnings Per Share (EPS) forecast of $1.10 for the next financial year.
What is the trend in the Taro Pharmaceutical Industries share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Taro Pharmaceutical Industries. Over the past six months, its share price has outperformed the S&P500 Index by +3.18%.
As of the last closing price of $42.04, shares in Taro Pharmaceutical Industries were trading +7.9% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Taro Pharmaceutical Industries PE Ratio?
The Taro Pharmaceutical Industries PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $42.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries' management team is headed by:
- Dilip Shanghvi - CHM
- Uday Baldota - CEO
- Abhay Gandhi - VCH
- Erik Zwicker - VPR
- Michele Visosky - VPR
- Victoria Chester - VPR
- Itamar Karsenti - VPR
- Avi Avramoff - VRD
- Vikash Agarwal - VBD
- Jayesh Shah - OTH
- James Kedrowski - DRC
- Sudhir Valia - DRC
- Linda Benshoshan - IND
- Dov Pekelman - IND
- Robert Stein - IND